PavMed subsidiary Lucid will commercialize Case Western's EsoCheck technology to detect Barrett's esophagus, a precursor to esophageal cancer.
PavMed subsidiary Lucid Diagnostics secured exclusive global rights to develop and commercialize genetic biomarker-based diagnostic tests using EsoCheck technology.
Exome sequences from thousands of Chinese individuals with or without esophageal squamous cell carcinoma led to six new germline risk variants.
In an initial project, the research team is sequencing esophageal tumor genomes of patients in Tanzania, where it is one of the most common cancers.
Higher levels of oral bacteria like Tannerella forsythia and Porphyromonas gingivalis increased the risk of esophageal cancer, though other bacteria had protective effects.
The team found that cancer-causing genes depend on the BTK gene, which they believe they can shut down with an existing drug.
A new analysis hints that adenocarcinomas or squamous cell carcinomas may have certain overlapping expression patterns, regardless of the tissue of origin.
The five-year award will provide funding for researchers to investigate genetic determinants of Barrett's Esophagus and esophageal adenocarcinoma.
In Genome Research this week: esophageal adenocarcinoma sequencing study, the automated BLAST pipeline Leapfrog, and more.
The activity follows a recent financing round that has enabled OncoDNA to build out its sales team as it courts new clients.
US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.
Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.
In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.
In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.